Data for this Seminar were identified by searches of PubMed, Embase, Web of Science, and Cochrane Library for reports published between Nov 1, 2008, and March 31, 2013, online accessible abstract collections from 2012 annual meetings of the American Society of Haematology, American Society of Clinical Oncology, and European Society of Haematology. Search terms used were “myeloma”, “pathogenesis”, “diagnosis”, “treatment”, and “therapy”; MeSH terms and filters for randomised trials were used if
SeminarMultiple myeloma
Section snippets
Epidemiology
Multiple myeloma is the malignant counterpart of long-lived plasma cells with a strong tropism for bone and bone marrow. Among other plasma cell dyscrasias, such as Waldenström's macroglobulinaemia and primary amyloidosis, multiple myeloma is the second most frequent haematological malignancy with an age-adjusted incidence of six per 100 000 per year in the USA and Europe. The incidence of multiple myeloma is two to three times higher in African Americans, making it the most common
Pathogenesis
Multiple myeloma cells are similar to long-lived, post-germinal centre plasma cells, and are characterised by strong bone marrow dependence, extensive somatic hypermutation of immunoglobulin genes, and absence of IgM expression. However, multiple myeloma cells differ from healthy plasma cells because they retain the potential to return to a lower proliferative state.3
Symptoms, diagnostic workup, and disease monitoring
The most common clinical manifestations of symptomatic multiple myeloma are anaemia, infections, lytic or osteopenic bone disease, or renal failure, but patients with multiple myeloma might be diagnosed at an asymptomatic stage by chance. Generally, multiple myeloma is diagnosed at an earlier stage today than in the past.8 Back pain, particularly in older patients, or unclear anaemia should prompt screening for the presence of multiple myeloma. The standard screening workup includes total serum
Indication for treatment
Patients with smouldering multiple myeloma have no treatment indication and should be monitored for disease progression because early treatment with conventional therapy has shown no benefit.17, 18, 19 The risk of progression is highest in the first 5 years and decreases subsequently. The overall risk of progression is 10% per year for the first 5 years, about 3% per year for the next 5 years, and 1% per year for the next 10 years.17 Patients with high-risk smouldering multiple myeloma should
Future perspectives
The growing knowledge about pathogenic mechanisms, the development of novel effective compounds that target both multiple myeloma cells and the microenvironment, and more effective supportive strategies have led to a prolonged median overall survival of patients with multiple myeloma over the past two decades.107 As shown in a single treatment centre, 5-year overall survival improved from 37% in patients treated between 1971 and 1996, to 52% between 1997 and 2006 (figure 4), and 66% between
Search strategy and selection criteria
References (109)
- et al.
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States
Blood
(2006) - et al.
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
Blood
(2013) - et al.
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides
Blood
(2012) - et al.
Changing clinical presentation of multiple myeloma
Eur J Cancer
(1991) - et al.
What do I need to know about immunoglobulin light chain (AL) amyloidosis?
Blood Rev
(2012) - et al.
Systemic light chain amyloidosis: an update for treating physicians
Blood
(2013) - et al.
Current approach to diagnosis and management of acute renal failure in myeloma patients
Adv Chronic Kidney Dis
(2012) - et al.
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
Lancet
(2010) - et al.
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
Blood
(2012) - et al.
Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma
Blood
(2009)